Padlock Therapeutics, a biotechnology company dedicated to creating new medicines for destructive autoimmune diseases, today announced the appointment of Kerri Mowen, Ph.D., one of the Company’s scientific cofounders, to the newly created position of Director of Biology. Dr. Mowen is a leading expert in the biology of protein-arginine deiminase (PAD) enzymes. Recent advances in PAD biology and biochemistry, including work by Padlock’s scientific co-founders, have enabled pursuit of rational development of inhibitors of these enzymes for the treatment of autoimmune and inflammatory disease.
